Embecta declares quarterly dividend of $0.15 per share

PARSIPPANY, N.J. - Embecta Corp. (NASDAQ:EMBC) announced Friday that its Board of Directors has declared a quarterly cash dividend of $0.15 per share on the company’s common stock, maintaining its attractive 5.79% dividend yield. The company has demonstrated consistent shareholder returns despite its stock trading near 52-week lows.

The dividend will be paid on September 15, 2025, to stockholders of record as of the close of business on August 29, 2025, according to a company press release.

Embecta, which describes itself as a medical supplies company with roots in insulin delivery, has approximately 2,000 employees globally. The company states it has a 100-year legacy in the insulin delivery sector and is working to expand its presence in the broader medical supplies market.

The quarterly dividend announcement represents a routine financial update for the company’s shareholders. With a market capitalization of approximately $605 million, Embecta trades on the Nasdaq stock exchange under the ticker symbol EMBC.

In other recent news, Embecta Corp reported its second-quarter fiscal year 2025 earnings, surpassing expectations with an EPS of $0.70, higher than the forecasted $0.53. Revenue for the quarter was $259 million, slightly exceeding the anticipated $253.86 million, though it marked a 9.8% decline year-over-year. The revenue decline was influenced by a forward shift in sales due to customers purchasing ahead of a price increase implemented on January 1. Additionally, a major U.S. pharmacy retailer’s decision to close stores is expected to impact Embecta’s revenue in the latter half of 2025.

Meanwhile, BofA Securities analyst Travis Steed lowered the price target for Embecta shares to $18.00 from $20.00, maintaining an Underperform rating. The adjustment reflects the company’s fiscal second-quarter revenue performance, which slightly exceeded expectations due to less severe foreign exchange headwinds. Despite the positive earnings surprise, investors showed concern over the declining revenue and market challenges. These recent developments highlight the mixed signals in Embecta’s financial performance and market outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.